Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline

Januzzi, J. et al. (2019) Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. European Journal of Heart Failure, 21(3), pp. 386-388. (doi: 10.1002/ejhf.1419) (PMID:30767353)

[img]
Preview
Text
176196.pdf - Accepted Version

450kB

Abstract

No abstract available.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Ferreira, Mr Joao and Petrie, Professor Mark
Authors: Januzzi, J., Ferreira, J. P., Böhm, M., Kaul, S., Wanner, C., Brueckmann, M., Petrie, M., Ofstad, A.-P., Zeller, C., George, J., Fitchett, D., and Zannad, F.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:European Journal of Heart Failure
Publisher:Wiley
ISSN:1388-9842
ISSN (Online):1879-0844
Published Online:14 February 2019
Copyright Holders:Copyright © 2019 The Authors
First Published:First published in European Journal of Heart Failure 21(3):386-388
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record